Hanmi Pharm (128940) Stock Outlook 2026: GLP-1 Pipeline & MSD Milestones
Hanmi Pharmaceutical (128940) 2026 outlook: GLP-1 obesity pipeline, efpeglenatide Phase 3, MSD license milestones, Lapscovery platform, IFRS R&D capitalization risk, and KRX investing guide for global investors.
128940 HanmiPharm KoreanStocks